Issue | Pharma's Almanac

Current Issue: Q2 2018

The Next-Generation Issue

Also In This Issue

22 State-of-the-Art Biologics Manufacturing in an Unexpected Location

DEK here: Members of the pharmaceutical industry have a responsibility to guarantee both the supply of high-quality medicines and the safety of their personnel. Servier has implemented a global business continuity management strategy to reduce the likelihood of incidents and minimize any consequent impact on its operations. Subtitle: Understanding Business Continuity Management (BCM) Business continuity […]

Biologics

Building a Biologics Business from the Ground Up

Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy. Polpharma has attracted world-recognized leaders to build and manage all key biologics funcions at its new, state-of-the-art facilities, which are located in Poland and in the Netherlands, ideally situated to serve the global markets. Backed by a strong […]

Hot Melt Extrusion

Leveraging Hot Melt Extrusion for Solubility and Continuous Manufacturing

Hot melt extrusion (HME) technology has become a key solution to adding absorption for enhanced solubility. HME is also a continuous process, which has been encouraged by the FDA.1 Companies lacking in this particular expertise are encouraged to seek out a firm with proven authority in the space, such as Foster Delivery Science. Foster […]

Next-Generation Therapeutics

Getting Next-Generation Therapies into the Hands of Patients – The Industry Takes on Big Challenges

In this, our second issue of 2018, we explore the next-generation ther- apeutics that are demonstrating great potential to not only treat but to cure previously untreatable diseases. The industry faces numerous challenges to bring these novel medicines to market, and many innovative companies, from start-ups to established big pharma firms, are developing innovative technologies […]

Mergers & Acquisitions

Inside Mergers & Acquisitions

Innovation and efficiency are both key to successful drug development and commercialization. In addition to internal investment in R&D, mergers and acquisitions and licensing deals are fundamental strategies for gaining access to novel therapeutic compounds and platform technologies that can expand pipeline portfolios and broaden market reach. These factors apply to both pharma companies and […]

Next-Generation Biopharma

Changes in the Biopharma Industry: from Minor to Major Evolution

NICE INSIGHT OVERVIEW: Market Growth The biopharmaceutical industry continues to grow rapidly. Targeted biologics are helping treat previously untreatable diseases. New technologies such as gene editing are leading to the development of even more advanced, targeted medicines. The application of artificial intelligence is helping to reduce costs and increase efficiencies across the entire biopharmaceutical value chain. […]

Clinical Trials

Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

Industry Leader Insight: Supply Chain Solutions Direct-to-Patient (DTP) clinical trials are rapidly becoming the industry standard, with many trials underway today offering DTP options. Comprehensive support of these complex trials requires a logistics provider with the expertise, resources and network to safeguard the entire supply chain — from the manufacturing point-of-origin through the last mile. […]

Investment

Taking Middle-Market CROs and CDMOs to the Next Level

Small CDMOs and CROs that have achieved profits in the $5 to $20 million USD range often need assistance moving to the next level. Investment firms like Castleford Capital that focus on lower-middle-market companies in this sector have the capital, relationships and operational resources needed by executives to enable further growth. Industry Trends Underscore Need […]

Biologic Candidates

Addressing Development Challenges for Complex Biologic Drug Candidates

Biologic drugs are increasingly complex, creating numerous difficulties for biopharmaceutical companies from higher candidate failure rates to expression and manufacturing challenges. As a full-service contract development and manufacturing organization (CDMO), Lonza has the tools, techniques, capabilities and flexible capacity to help our customers overcome these hurdles and reduce the time for projects to move from […]

Viral Vector

Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

Next-generation viral vector and gene therapy manufacturing facilities must be sufficiently flexible to work with a range of viral technologies, cell-culture processes, downstream unit operations and fill/finish systems over a wide range of scales — and do so under high-containment conditions. Fujifilm Diosynth Biotechnologies has mobile, modular multiproduct facilities that can support product development to […]

Past Issues

View all Past Issues

Future Pharma Partner Models

View Issue »

Issue #3 | Volume #3 | Q3 2017

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020

The Networking Issue

View Issue »

Issue #3 | Volume #5 | Q3 2019

The Innovation Issue

View Issue »

Issue #4 | Volume #4 | Q4 2018